A US study has found that people with Attention-Deficit Hyperactivity Disorder (ADHD) may have an increased risk of developing Parkinson's.
Researchers and drug companies have a new tool in the search for better treatments for Parkinson's - a brain scan that can be used to select the right people for clinical trials.
Researchers in America have developed an experimental drug, similar to compounds used to treat diabetes, that slows the progression of Parkinson's in a mouse model of the condition.
Researchers have discovered that nicotinamide riboside, a form of vitamin B3, may boost energy in nerve cells and help prevent them being lost in Parkinson's.
Further analysis of the results from a recent clinical trial of the type 2 diabetes drug exenatide in people with Parkinson's has revealed encouraging signs of a positive effect on mood.
The trial will test whether drug treatment with a commonly prescribed dementia drug can improve balance and walking and help to prevent falls in people with Parkinson's.
The latest update, one year into a clinical trial happening in Australia and New Zealand, show promising results for the safety and effectiveness of NTCELL® therapy.